Abstract

BackgroundPeritoneal dialysis (PD) is a treatment for end stage renal disease patients, but it can also cause peritoneal fibrosis. Nestin is known as a neural stem cell marker and it has many functions. The hypoxia induced factor (HIF) signaling pathway can be activated under hypoxia conditions, leading to the overexpression of some angiogenesis related genes. The aim of our study is to demonstrate Nestin’s role in the development of peritoneal fibrosis (PF), and to provide a new target (Nestin) to treat PF.MethodsPD mice models were constructed by an intraperitoneal administration of PDS at 10 ml/100g/d for 4 weeks. Nestin-positive cells were isolated from peritonea of Nestin-GFP mice by flow cytometry. The relationship of Nestin and HIF1-α-VEGFA pathway was detected by Nestin knockdown, Co-immunoprecipitation and immunofluorescence. Also, proteasomal activity was demonstrated by CHX and MG132 application, followed by Western blotting and Co-immunoprecipitation.ResultsIn our experiments, we found that Nestin expression resulted in PF. Also, HIF1-α/VEGFA pathway was activated in PF. Nestin knockdown reduced the level of HIF1-α. Nestin directly bound to HIF1-α and protected HIF1-α from proteasomal degradation. Overexpression of HIF1-α reverts the fibrosis levels in Nestin-knockdown cells. In brief, Nestin inhibited the degradation of HIF1-α by mitigating its ubiquitination level, leading to the activation of HIF1-α signaling pathway, and eventually promoted PF.ConclusionWe found a novel mechanism of PF that Nestin promotes by protecting HIF1-α from proteasomal degradation. Taken together, our key findings highlight a novel mechanism by which the silencing of Nestin hinders HIF1- α -induced PF.

Highlights

  • Peritoneal dialysis (PD) is one of the most important renal replacement therapies for end-stage renal disease patients, which uses the peritoneal membrane as a dialysis membrane (Mehrotra et al, 2016)

  • The immunohistochemistry (IHC) staining results showed that the expression of α-smooth muscle actin (α-SMA) and Nestin increased in the PD model group (Figure 1A)

  • The mRNA levels of α-SMA and Nestin showed a significant increase in the PD model group (Figures 1B,C)

Read more

Summary

Introduction

Peritoneal dialysis (PD) is one of the most important renal replacement therapies for end-stage renal disease patients, which uses the peritoneal membrane as a dialysis membrane (Mehrotra et al, 2016). Peritoneal dialysis accounts for about 15% of end-stage renal disease patients (Li et al, 2017). One of the common and serious adverse effects of peritoneal dialysis is peritoneal fibrosis (PF). The peritoneal mesothelial cell will lose its normal structure, function and morphology (Yáñez-Mó et al, 2003), leading to peritoneal fibrosis. Peritoneal dialysis (PD) is a treatment for end stage renal disease patients, but it can cause peritoneal fibrosis. The aim of our study is to demonstrate Nestin’s role in the development of peritoneal fibrosis (PF), and to provide a new target (Nestin) to treat PF

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.